Vincerx 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
enitociclib (VIP152) / Vincerx
NCT05371054: Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Active, not recruiting
1/2
130
US
Vysis LSI MYC Break Apart Rearrangement Probe Kit, venetoclax, VIP152, prednisone
National Cancer Institute (NCI)
Lymphoma, Non-Hodgkin Lymphoma, NHL, Hematologic Malignancies, Lymphoid Malignancies
07/24
07/29
VNC-152-101, NCT02635672: Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Completed
1
110
Europe, US, RoW
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, pembrolizumab, VIP152 (BAY 1251152) 15 mg
Vincerx Pharma, Inc.
Neoplasms
11/24
11/24
VNC-152-102, NCT04978779: A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Terminated
1
6
Europe, US
VIP152, BTKi
Vincerx Pharma, Inc.
Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Richter Syndrome, MYC Amplification, MYC Overexpression, MYC Translocation
05/23
05/23
VIP943 / Vincerx
VNC-943-101, NCT06034275: Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Jul 2022 - Dec 2023: Topline data from trial solid tumors
Recruiting
1
36
US
VIP943 (QW), VIP943 (BIW)
Vincerx Pharma, Inc.
Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome
05/25
12/25
VIP236 / Vincerx
NCT05712889: Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

Completed
1
29
US, RoW
VIP236 (Q3W), VIP236 (Q2W)
Vincerx Pharma, Inc.
Neoplasms
10/24
10/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
enitociclib (VIP152) / Vincerx
NCT05371054: Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Active, not recruiting
1/2
130
US
Vysis LSI MYC Break Apart Rearrangement Probe Kit, venetoclax, VIP152, prednisone
National Cancer Institute (NCI)
Lymphoma, Non-Hodgkin Lymphoma, NHL, Hematologic Malignancies, Lymphoid Malignancies
07/24
07/29
VNC-152-101, NCT02635672: Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Completed
1
110
Europe, US, RoW
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, pembrolizumab, VIP152 (BAY 1251152) 15 mg
Vincerx Pharma, Inc.
Neoplasms
11/24
11/24
VNC-152-102, NCT04978779: A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Terminated
1
6
Europe, US
VIP152, BTKi
Vincerx Pharma, Inc.
Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Richter Syndrome, MYC Amplification, MYC Overexpression, MYC Translocation
05/23
05/23
VIP943 / Vincerx
VNC-943-101, NCT06034275: Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Jul 2022 - Dec 2023: Topline data from trial solid tumors
Recruiting
1
36
US
VIP943 (QW), VIP943 (BIW)
Vincerx Pharma, Inc.
Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome
05/25
12/25
VIP236 / Vincerx
NCT05712889: Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

Completed
1
29
US, RoW
VIP236 (Q3W), VIP236 (Q2W)
Vincerx Pharma, Inc.
Neoplasms
10/24
10/24

Download Options